CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 156 enrolled
Drug / intervention
Dronabinol +1 moredrug
Likely dose
Dronabinol (specific dose not specified in trial record)AI-extracted
Key inclusion· 4
  • ✓Age 18–60 years
  • ✓Meets DSM-IV criteria for current marijuana dependence with marijuana as primary drug of abuse
  • ✓Uses marijuana at least 5 days per week with positive urine drug screen at study entry
  • ✓Capable of informed consent and complying with study procedures
Key exclusion· 10
  • ✕Current psychiatric disorder requiring psychiatric intervention (stable disorders on therapy acceptable)
  • ✕History of seizures
  • ✕Known sensitivity to dronabinol
  • ✕Physical dependence on other drugs (excluding nicotine) requiring medical detoxification

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00217971
NCT00217971Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction

New York State Psychiatric Institute·interventional·Posted Sep 22, 2005·Updated Apr 24, 2019

In Brief

A Phase 2 clinical trial evaluating Dronabinol and Placebo for Marijuana Abuse. Completed, enrolled 156 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 22, 2005
Enrollment StartMar 1, 2005
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.8 years ago

Interventions

Dronabinoldrug

Dronabinol

Placebodrug

placebo